UCSF Education for Healthcare Providers on Care and Research During COVID-19
Course video and enrollment
Return to Care

Learn More

Course Videos

Planning Committee Disclosures

Overview and Learning Objectives

CME Credit

Cultural and Linguistic Competency

Want to see more like this? View additional CME offerings

Developing Therapies for COVID-19: Understanding the mechanisms of attack to inform treatment

To begin the course, play the video below. There is a link below the video to complete the evaluation and post-test if you want to receive credit for this activity.

Starts On: 8/5/2020
Ends On: 8/4/2021
Session Type: Internet Activity Enduring Material
Course Number: MED23088D
Credits: 1.50

For Credit, complete the evaluation and post-test

This activity originated as a presentation at the CME activity, UCSF Osher Mini Medical School, May 6, 2020.

Learning Objectives

  • Describe the challenges to traditional approaches to therapeutic agent development;
  • Describe an approach to identification of viral-host interactions;
  • Describe an approach to identification of therapeutic agents that target identified viral-host interactions.

Faculty & Planning Committee

Kevan Shokat, PhD
Howard Hughes Medical Institute, Department of Cellular and Molecular Pharmacology, UCSF

Nevan Krogan, PhD
QBU Director, Gladstone Institute Investigator, Department of Cellular and Molecular Pharmacology, UCSF

Brian Shoichet, PhD
Department of Pharmaceutical Chemistry, UCSF

Jacqueline Fabius
QBI COO, School of Pharmacy, UCSF

Disclosure of Financial Relationships:

Kevan Shokat, PhD
Consultant: Araxes/Wellspring Biosciences, Revolution Medicines, Genentech/Roche, Erasca, Denali, Janssen, Merck, Kumquat, Nextech, Opal Biosciences
Stock Shareholder: Araxes/Wellspring Biosciences, Kura Oncology, eFFECTOR Therapeutics, Revolution Medicines, Mitokinin, Dice, Erasca, Denali, Kumquat, Nextech, Opal Biosciences

Nevan Krogan, PhD
Consultant:  Maze Therapeutics, Inc.
Stock Shareholder: Maze Therapeutics, Inc., Tenaya Therapeutics

Brian Shoichet, PhD
Consultant/SAB/Speaking/Patent Litigation Fees: Schroedinger, Roche, Vertex, BlueDolphin Leads, Patent litigation
Stock Shareholder: Epiodyne, BlueDolphin Leads

Jacqueline Fabius
Nothing to Disclose

Accreditation Information

The University of California, San Francisco School of Medicine (UCSF) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

UCSF designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™.   Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: For the purposes of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME.

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 credit™ from organizations accredited by the ACCME.

Pharmacy: The California Board of Pharmacy accepts as continuing professional education those courses that meet the standard of relevance to pharmacy practice and have been approved for AMA PRA Category 1 Credits™.